Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Dextran Sulfate
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Dextran Sulfate

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 6 min read

Long-chain polymer of glucose containing 17-20% sulfur.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (1,119 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Long-chain polymer of glucose containing 17-20% sulfur. It has been used as an anticoagulant and also has been shown to inhibit the binding of hiv-1 to cd4-positive t-lymphocytes. It is commonly used as both an experimental and clinical laboratory reagent and has been investigated for use as an antiviral agent, in the treatment of hypolipidemia, and for the prevention of free radical damage, among other applications.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Sulfate, Dextran; Dextran Sulfate Sodium; Sulfate Sodium, Dextran; Sodium Dextran Sulfate; Dextran Sulfate, Sodium; Sulfate, Sodium Dextran.

Where it fits in the MeSH classification

Broader topics
Dextrans

Related concepts

  • Hiv-1
  • Cd4-Positive T-Lymphocytes

Research landscape

PubMed indexes 10,369 records tagged with the MeSH heading “Dextran Sulfate” (counts retrieved 2026-10-31). 4,978 of them (48.0%) were published from 2020 onward, and the busiest period so far is 2020 onward with 4,978 records.

Reviews account for 84 records (0.8%) and meta-analyses for 4. Randomized controlled trials number 10 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 1,068 records; 2000-2009: 1,102 records; 2010-2019: 3,221 records; 2020 onward: 4,978 records1,068through 19991,1022000-20093,2212010-20194,9782020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19991,068
2000-20091,102
2010-20193,221
2020 onward4,978
Share of records by publication typeReviews: 0.8 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 0.1 percentReviews0.8% (84)Meta-analyses0.0% (4)Randomized controlled trials0.1% (10)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 10,369 PubMed records
TypeRecordsShare
Reviews840.8%
Meta-analyses40.0%
Randomized controlled trials100.1%

Method: PubMed query "Dextran Sulfate"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation
Qu S, Fan L, Qi Y, Xu C, Hu Y, Chen S, et al.
2021Research article
Design not recorded in structured metadata
204cc by
PMID 34612661 · DOI · PMC8510245
Exosomes Derived From M2b Macrophages Attenuate DSS-Induced Colitis
Yang R, Liao Y, Wang L, He P, Hu Y, Yuan D, et al.
2019Research article
Design not recorded in structured metadata
160cc by
PMID 31749791 · DOI · PMC6843072
Gut microbiota drives the attenuation of dextran sulphate sodium-induced colitis by Huangqin decoction
Yang Y, Chen G, Yang Q, Ye J, Cai X, Tsering P, et al.
2017Research article
Design not recorded in structured metadata
92cc by
PMID 28415628 · DOI · PMC5564731
Dextran sodium sulfate confounds causal role of periodontitis in inflammatory bowel disease
Tanwar H, Gnanasekaran JM, Ganesh N, Zhou C, Plotkin A, Baima G, et al.
2026Research article
Design not recorded in structured metadata
3cc by
PMID 41363709 · DOI · PMC13169473

Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation [1]

Research article Qu S, Fan L, Qi Y, Xu C, Hu Y, Chen S, et al. · · 2021 · cited 204 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Akkermansia muciniphila has been proved to play a crucial role in the progression of colitis, but its underlying mechanism remains inconclusive.
Closing excerpt
muciniphila and provide guidance for the treatment of human colitis in the future.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (390 words)

Akkermansia muciniphila has been proved to play a crucial role in the progression of colitis, but its underlying mechanism remains inconclusive. In this study, we aim to investigate the effect of A. muciniphila on the development of acute colitis and explore the underlying mechanism. We found that the fecal level of A. muciniphila was decreased in ulcerative colitis (UC) patients compared to the healthy people in the GMrepo database. Oral administration of A. muciniphila strain BAA-835 significantly ameliorated the symptoms in dextran sulfate sodium (DSS)-induced acute colitis, evidenced by decreased body weight loss, colon length shortening, and colon histological inflammatory score. In addition, the number of goblet cells and the mucin family were enhanced after A. muciniphila treatment. Furthermore, proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein 1 (MCP-1) had a downward trend. Mechanistically, the expression of NLRP3, caspase-1 p20, and IL-1β p17 were upregulated in A. muciniphila-treated mice. Additionally, the colon tissues from high-A. muciniphila UC patients had a higher NLRP3 expression than that from low-A. muciniphila UC patients. Moreover, the upregulation of NLRP3 was observed in mouse macrophage Raw264.7 cells and bone marrow-derived macrophage (BMDM) cells after incubation with A. muciniphila. To clarify whether the protective effect of A. muciniphila in colitis depends on NLRP3, we performed the NLRP3-deficient assay in NLRP3-/- mice in vivo. The evidence showed that NLRP3 deficiency eliminated the protective effects of A. muciniphila in acute colitis. In conclusion, A. muciniphila alleviates DSS-induced acute colitis by NLRP3 activation, which enriches the mechanism and provides a new prospect for the probiotic-based treatment of colitis. IMPORTANCE The gut microbiota and host immune response interaction influences the progression of intestinal inflammatory disease. As a well-recognized next-generation probiotic, Akkermansia muciniphila has been proved to play a crucial role in the progression of colitis, but its underlying mechanism remains inconclusive. We found that oral administration of A. muciniphila strain BAA-835 significantly ameliorated the symptoms of acute colitis. Mechanistically, the expression of NLRP3 was upregulated in the A. muciniphila group, and the protective effect of A. muciniphila in colitis depends on NLRP3 activation. This enriches the mechanism and provides a new prospect for the probiotic-based treatment of colitis, which would promote a deeper understanding of the complex characteristics of A. muciniphila and provide guidance for the treatment of human colitis in the future.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34612661 · DOI · PMC8510245

Exosomes Derived From M2b Macrophages Attenuate DSS-Induced Colitis [2]

Research article Yang R, Liao Y, Wang L, He P, Hu Y, Yuan D, et al. · · 2019 · cited 160 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Macrophages are commonly classified as M1 macrophages or M2 macrophages.
Closing excerpt
These findings provide a novel approach for the treatment of IBD.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (228 words)

Macrophages are commonly classified as M1 macrophages or M2 macrophages. The M2 macrophages are further sub-categorized into M2a, M2b, M2c, and M2d subtypes. The M2a, M2b, and M2c subtypes play roles in anti-inflammatory activity, tissue remodeling, type 2 T helper cell (Th2) activation, and immunoregulation. Previous studies have shown that macrophage exosomes can affect some disease processes. Exosomes are 30-150-nm lipid bilayer membrane vesicles derived from most living cells, with important biological functions. The role of exosomes in preventing the development of autoimmune diseases, including inflammatory bowel disease (IBD), has evoked increasing interest. Here, we analyze the roles of exosomes derived from M2a, M2b, and M2c macrophage phenotypes in dextran sulfate sodium (DSS)-induced colitis. Exosomes were isolated from the supernatant of different types of macrophages and identified via transmission electron microscopy (TEM), western blotting, and NanoSight. The results showed that M2b macrophage exosomes significantly attenuated the severity of DSS-induced colitis in mice. The number of regulatory T (Treg) cells in the spleens of mice with colitis and levels of IL-4 both increased following treatment with M2b macrophage exosomes. In addition, key cytokines associated with colitis (IL-1β, IL-6, and IL-17A) were significantly suppressed, following treatment with M2b macrophage exosomes. The M2b macrophage exosomes exerted protective effects on DSS-induced colitis, mainly mediated by the CC chemokine 1 (CCL1)/CCR8 axis. These findings provide a novel approach for the treatment of IBD.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31749791 · DOI · PMC6843072

Gut microbiota drives the attenuation of dextran sulphate sodium-induced colitis by Huangqin decoction [3]

Research article Yang Y, Chen G, Yang Q, Ye J, Cai X, Tsering P, et al. · · 2017 · cited 92 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The gut microbiota, including probiotics and pathogenic microorganisms, is involved in ulcerative colitis (UC) by regulating pathogenic microorganisms and the production of intestinal mucosal antibodies.
Closing excerpt
In conclusion, our results suggest that HQD could ameliorate DSS-induced inflammation through alteration of the gut microbiota.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (188 words)

The gut microbiota, including probiotics and pathogenic microorganisms, is involved in ulcerative colitis (UC) by regulating pathogenic microorganisms and the production of intestinal mucosal antibodies. Huangqin decoction (HQD), a traditional Chinese formula chronicled in the Shanghan lun, has been recognized as an effective drug for UC, owing to its anti-inflammatory and anti-oxidative properties. In the present study, we investigated whether HQD ameliorates dextran sulphate sodium (DSS)-induced colitis through alteration of the gut microbiota. We found that HQD significantly inhibited colitis, alleviating the loss of body weight, disease activity index, colon shortening, tissue injury, and inflammatory cytokine changes induced by DSS treatment. Principal component analysis and principal co-ordinate analysis showed an obvious difference among the groups, with increased diversity in the DSS and DSS+HQD groups. Linear discriminant analysis effect size was used to determine differences between the groups. The relative abundance of Lactococcus was higher in the DSS+HQD group than in the DSS group, whereas Desulfovibrio and Helicobacter were decreased. Furthermore, the protective effect of HQD was attenuated only in antibiotic-treated mice. In conclusion, our results suggest that HQD could ameliorate DSS-induced inflammation through alteration of the gut microbiota.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 28415628 · DOI · PMC5564731

Dextran sodium sulfate confounds causal role of periodontitis in inflammatory bowel disease [4]

Research article Tanwar H, Gnanasekaran JM, Ganesh N, Zhou C, Plotkin A, Baima G, et al. · · 2026 · cited 3 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundEmerging evidence supports a bidirectional link between periodontitis and inflammatory bowel disease (IBD).
Closing excerpt
These findings reveal that DSS alone can affect the mouth and may confound studies investigating links between gum disease and inflammatory bowel disease, highlighting the need for better-controlled models.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (313 words)

BackgroundEmerging evidence supports a bidirectional link between periodontitis and inflammatory bowel disease (IBD). To investigate this relationship, experimental models commonly use dextran sodium sulfate (DSS) to induce colitis. However, DSS is presumed to selectively affect the colon, and its potential off-target effects on the oral cavity remain poorly understood. We examined whether DSS disrupts oral health, potentially confounding oral-gut axis research.MethodsC57BL/6 mice received 2% DSS in drinking water for 8 days, followed by 2 days of untreated water. Colitis severity was assessed by weight loss, colon length, histopathology, and quantitative real-time-polymerase chain reaction (qRT-PCR). Oral health was evaluated via micro-computed tomography (micro-CT) analysis of alveolar bone, gingival histology, cytokine expression, and 16S rRNA sequencing of the oral microbiome.ResultsDSS induced hallmark features of colitis, including weight loss, colon shortening, epithelial crypt damage, and mucosal inflammation. Strikingly, DSS also induced significant oral pathology, including alveolar bone loss, gingival epithelial hyperplasia, inflammatory infiltration, and upregulated gingival pro-inflammatory cytokines (interleukin [IL] -6, IL-17, tumor necrosis factor-alpha [TNF-α]). DSS further altered the oral microbiota causing reduced alpha-diversity and a dysbiotic shift, with enrichment of Streptococcus danieliae and depletion of commensals such as Lactobacillus murinus and Clostridium ASF502. These microbial changes were accompanied by upregulated pathways involved in carbohydrate metabolism, oxidative stress response, and environmental sensing.ConclusionDSS induces periodontal inflammation and oral dysbiosis, independent of colitis. These findings expose a critical confounder in oral-gut axis models and highlight the need to include DSS-only or periodontitis-only controls and alternative models to accurately distinguish systemic effects of DSS from true oral-gut interactions.Plain language summaryThis study shows that dextran sodium sulfate (DSS), a chemical used to model gut inflammation in mice, also causes gum disease-like changes-including bone loss, inflammation, and changes in oral bacteria. These findings reveal that DSS alone can affect the mouth and may confound studies investigating links between gum disease and inflammatory bowel disease, highlighting the need for better-controlled models.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41363709 · DOI · PMC13169473

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Dextran sodium sulphate colitis mouse model: traps and tricks [5]
    Perše M, Cerar A · J Biomed Biotechnol · 2012 · cited 660 times (Europe PMC)
  • Research article Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model [6]
    Yang C, Merlin D · Inflamm Bowel Dis · 2024 · cited 162 times (Europe PMC)
  • Research article Murine Model for Colitis-Associated Cancer of the Colon [7]
    Snider AJ, Bialkowska AB, Ghaleb AM, Yang VW, Obeid LM, Hannun YA · Methods Mol Biol · 2016 · cited 94 times (Europe PMC)
  • Research article Colloidal polyelectrolyte complexes of chitosan and dextran sulfate towards versatile nanocarriers of bioactive molecules [8]
    Delair T · Eur J Pharm Biopharm · 2011 · cited 82 times (Europe PMC)
  • Research article Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation [9]
    Spirig R, Gajanayake T, Korsgren O, Nilsson B, Rieben R · Mol Immunol · 2008 · cited 25 times (Europe PMC)
  • Research article Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus [10]
    Kutsuki H, Takata S, Yamamoto K, Tani N · Ther Apher · 1998 · cited 19 times (Europe PMC)

References

  1. Qu S, Fan L, Qi Y, Xu C, Hu Y, Chen S, et al.. Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation. . 2021. PMID 34612661 · DOI · PMC8510245
  2. Yang R, Liao Y, Wang L, He P, Hu Y, Yuan D, et al.. Exosomes Derived From M2b Macrophages Attenuate DSS-Induced Colitis. . 2019. PMID 31749791 · DOI · PMC6843072
  3. Yang Y, Chen G, Yang Q, Ye J, Cai X, Tsering P, et al.. Gut microbiota drives the attenuation of dextran sulphate sodium-induced colitis by Huangqin decoction. . 2017. PMID 28415628 · DOI · PMC5564731
  4. Tanwar H, Gnanasekaran JM, Ganesh N, Zhou C, Plotkin A, Baima G, et al.. Dextran sodium sulfate confounds causal role of periodontitis in inflammatory bowel disease. . 2026. PMID 41363709 · DOI · PMC13169473
  5. Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012. PMID 22665990 · DOI · PMC3361365
  6. Yang C, Merlin D. Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model. Inflamm Bowel Dis. 2024. PMID 38280217 · DOI · PMC11063560
  7. Snider AJ, Bialkowska AB, Ghaleb AM, Yang VW, Obeid LM, Hannun YA. Murine Model for Colitis-Associated Cancer of the Colon. Methods Mol Biol. 2016. PMID 27150094 · DOI · PMC5657253
  8. Delair T. Colloidal polyelectrolyte complexes of chitosan and dextran sulfate towards versatile nanocarriers of bioactive molecules. Eur J Pharm Biopharm. 2011. PMID 21138767 · DOI
  9. Spirig R, Gajanayake T, Korsgren O, Nilsson B, Rieben R. Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. Mol Immunol. 2008. PMID 18722664 · DOI
  10. Kutsuki H, Takata S, Yamamoto K, Tani N. Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus. Ther Apher. 1998. PMID 10227784 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • DextransDrugs and Chemicals
  • CellobioseDrugs and Chemicals
  • CelluloseDrugs and Chemicals
  • CyclodextrinsDrugs and Chemicals
  • GlucansDrugs and Chemicals
  • InulinDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

10,369
PubMed records on this heading
48%
published since 2020
84
review articles
10
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • DextransDrugs and Chemicals
  • CellobioseDrugs and Chemicals
  • CelluloseDrugs and Chemicals
  • CyclodextrinsDrugs and Chemicals
  • GlucansDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support